Search Results

1-6 of 6 results for primarymember:"Patsy Calton"

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Health, if he will amend the Cancer Patient Information Strategy to ensure that information on (a) diagnosis and (b) treatment is available for all people affected by (i) breast cancer and (ii) cancer in general who want it.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

17 November 2003

Reference

137454; 413 c575-6W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to expedite the review of (a) Seroxat and (b) other selective serotonin reuptake inhibitors; what plans he has to improve the warnings given to (a) prescribers and (b) the public about the (i) side-effects and (ii) withdrawal effects...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

12 June 2003

For answer on

20 June 2003

Answered on

20 June 2003

Mrs. Calton: To ask the Secretary of State for Health (1) what plans he has to expedite the review of (a) Seroxat and (b) other selective serotonin reuptake inhibitors; [119777] (2) what plans he has to improve the warnings given to (a) prescribers and (b) the public about the (i) side-effects and (ii) withdrawal effects of (A) Seroxat and (B) other selective serotonin reuptake inhibitors; [119778] (3) what plans he has to improve the effectiveness of the Yellow Card scheme for reporting adverse side- effects of drugs; [119779] (4) if he will withdraw Seroxat from use for new prescribing pending a review of its and other SSRI anti- depressants' safety. [119780] Dr. Ladyman: A new expert group of the Committee on Safety of Medicines (CSM) has been convened to further review the safety of selective serotonin re-uptake inhibitors (SSRIs) and to ensure the advice in the product information for both patients and prescribers is optimal for the safe use of these products. This group has been asked to examine what implications, if any, the CSM's recent advice on the use of Seroxat in children have for the use of Seroxat in adults and for other SSRIs. The timetable for the group's programme of work has been planned with a view to the availability of advice as promptly as possible, commensurate with a full and detailed consideration of the evidence including the experiences of patients. As part of its initial considerations, the group has advised on strengthened advice on side effects and withdrawal reactions for inclusion in the patient information leaflet on Seroxat. Product information for other SSRIs will also be considered. The advice of the CSM, most recently in 2001, is that the benefits of Seroxat, when used in adults for licensed indications, outweigh the risks. Regulatory authorities world-wide have also taken a similar position. Depression and anxiety disorders are serious conditions that can cause severe suffering and are associated with an increased risk of suicide. The availability of effective treatments is critically important. In the absence of evidence indicating that the risks of using Seroxat in adults outweigh the benefits, it would be difficult to justify withdrawing the medicine from use. The Yellow Card Scheme is recognised to be one of the best in the world in terms of the level of reporting, has a proven track record of identifying new drug safety hazards and enables the monitoring of all medicines, including Seroxat, in clinical use. The effectiveness of the Scheme is under continuous review by the Medicines and Healthcare products Regulatory Agency and the CSM. From April 2003, the first phase of patient reporting of suspected adverse drug reactions via NHS Direct was introduced. When fully rolled out in England and Wales, this will enable the first hand experiences of patients to be utilised in the identification and assessment of drug safety issues. Other measures to further strengthen the Yellow Card Scheme include a new regional monitoring centre, established in Scotland last year and the inclusion of education on yellow card reporting in the training of nurse prescribers.

Date

20 June 2003

Reference

407 c488-9W;407 c489-90W; 119777;119778;119779;119780

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, how many NHS-funded training programmes provide guidance on dealing with patient requests for a medically assisted suicide or voluntary euthanasia.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

27 March 2003

Reference

104560; 402 c388W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what procedures are in place for NHS Direct staff dealing with patients' enquiries relating to assisted suicides or voluntary euthanasia.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

27 March 2003

Reference

104537; 402 c388W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what advice he gives to the public on (a) eating lamb and (b) the possible link between scrapie and CJD.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

17 December 2002

Reference

396 c782W; 86906

House

House of Commons

Dept for Work and Pensions

To ask the Secretary of State for Work and Pensions, if he will ensure that regular statements are issued showing the outstanding balance on budgeting loans; if he will amend the repayment formulae to allow the option of more modest repayment rates; if he will (a) increase the maximum possible...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department for Work and Pensions

Type

Written questions

Status

Answered

Date

7 November 2002

Reference

392 c664W;392 c677-8W; 79218;79219;79220

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher